<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063230</url>
  </required_header>
  <id_info>
    <org_study_id>D1532C00082</org_study_id>
    <nct_id>NCT02063230</nct_id>
  </id_info>
  <brief_title>To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects</brief_title>
  <official_title>An Open-label, Comparative Study to Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY-142886) (Hyd-Sulfate) Following Single Oral Dosing to Healthy Subjects and to Subjects With Mild, Moderate, and Severe Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244,
      ARRY-142886) in patients with hepatic impairment and healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label study to assess the pharmcokinetics, safety and tolerability of a single dose
      of Selumetinib (AZD6244, ARRY-142886) in patients with hepatic impairment and healthy
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (0 to Infinity) of Total Selumetinib</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Total Selumetinib</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Normalized AUC, Total Selumetinib</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Normalized Cmax, Total Selumetinib</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Normalized AUC, Unbound Selumetinib</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Normalized Cmax, Unbound Selumetinib</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Selumetinib HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers (HV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selumetinib mild impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild (Child Pugh A) hepatic impaired patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selumetinib moderate impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate (Child Pugh B) hepatic impaired patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selumetinib severe impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe (Child Pugh C) hepatic impairment patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selumetinib 50mg</intervention_name>
    <description>HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1</description>
    <arm_group_label>Selumetinib HV</arm_group_label>
    <arm_group_label>Selumetinib mild impairment</arm_group_label>
    <arm_group_label>Selumetinib moderate impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selumetinib 25mg</intervention_name>
    <description>Severe (Child Pugh C) hepatic impaired patients will receive selumetinib 25mg orally on Day 1</description>
    <arm_group_label>Selumetinib severe impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for all participants:

          1. Subjects will be males or females (non-childbearing potential) aged 18 years or more
             and with a weight of at least 45 kg and a BMI between 18 and 40 kg/m2 inclusive.

             Inclusion Critera only for hepatic impaired patients:

          2. Subjects with stable liver cirrhosis and hepatic impairment for at least 3 months
             prior to the start of the study.

             Inclusion Criteria only for healthy volunteers:

          3. Subjects must be in good health, as determined by a medical history, physical
             examination, 12-lead ECG, clinical laboratory evaluations, and an ophthalmic
             examination performed before the administration of the investigational product.

        Exclusion Criteria for all participants:

          1. Subjects of Japanese or non-Japanese Asian ethnicity

          2. Any one parent or grandparent (maternal or paternal) is Japanese or non-Japanese Asian
             (eg, China, Taiwan, Korea, Philippines, Thailand, Vietnam, and Malaysia). Asian
             Indians are acceptable.

          3. Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks
             of the first administration of the investigational product

          4. Subjects who smoke more than 10 cigarettes or the equivalent in tobacco per day.

             Exclusion criteria for hepatic impaired patients only

          5. Undergone liver transplantation. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas C Marbury, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orlando Clinical Research Center, 5055 S Orange Avenue, Orlando, Florida, United States.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian Smith, MD</last_name>
    <role>Study Director</role>
    <affiliation>Astrazeneca, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <results_first_submitted>October 5, 2015</results_first_submitted>
  <results_first_submitted_qc>October 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 2, 2015</results_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I, healthy, pharmacokinetic, hepatic impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mild</title>
          <description>Mild (Child Pugh A) hepatic impaired subjects (all subjects received Selumetinib 50 mg)</description>
        </group>
        <group group_id="P2">
          <title>Moderate</title>
          <description>Moderate (Child Pugh B) hepatic impaired subjects). 6 subjects received Selumetinib 50 mg, 2 received Selumetinib 25mg</description>
        </group>
        <group group_id="P3">
          <title>Severe</title>
          <description>Severe (Child Pugh C) hepatic impaired subjects. All subjects received Selumetinib 20mg.</description>
        </group>
        <group group_id="P4">
          <title>Normal</title>
          <description>Healthy volunteers. All volunteers received Selumetinib 50mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mild</title>
          <description>Mild (Child Pugh A) hepatic impaired subjects (all subjects received Selumetinib 50 mg)</description>
        </group>
        <group group_id="B2">
          <title>Moderate</title>
          <description>Moderate (Child Pugh B) hepatic impaired subjects). 6 subjects received Selumetinib 50 mg, 2 received Selumetinib 25mg</description>
        </group>
        <group group_id="B3">
          <title>Severe</title>
          <description>Severe (Child Pugh C) hepatic impaired subjects. All subjects received Selumetinib 20mg.</description>
        </group>
        <group group_id="B4">
          <title>Normal</title>
          <description>Healthy volunteers. All volunteers received Selumetinib 50mg.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="4"/>
                    <measurement group_id="B2" value="57" spread="5"/>
                    <measurement group_id="B3" value="55" spread="9"/>
                    <measurement group_id="B4" value="57" spread="7"/>
                    <measurement group_id="B5" value="56" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC (0 to Infinity) of Total Selumetinib</title>
        <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post dose</time_frame>
        <population>In the moderate group, 2 patients received Selumetinib 25mg and are not included here but are included in the Dose Normalised AUC outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Mild</title>
            <description>Mild (Child Pugh A) hepatic impaired subjects (all subjects received Selumetinib 50 mg)</description>
          </group>
          <group group_id="O2">
            <title>Moderate</title>
            <description>Moderate (Child Pugh B) hepatic impaired subjects). 6 subjects received Selumetinib 50 mg, 2 received Selumetinib 25mg</description>
          </group>
          <group group_id="O3">
            <title>Severe</title>
            <description>Severe (Child Pugh C) hepatic impaired subjects. All subjects received Selumetinib 20mg.</description>
          </group>
          <group group_id="O4">
            <title>Normal</title>
            <description>Healthy volunteers. All volunteers received Selumetinib 50mg.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0 to Infinity) of Total Selumetinib</title>
          <population>In the moderate group, 2 patients received Selumetinib 25mg and are not included here but are included in the Dose Normalised AUC outcome measure</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2300" spread="38.9"/>
                    <measurement group_id="O2" value="4300" spread="45.3"/>
                    <measurement group_id="O3" value="1680" spread="19.9"/>
                    <measurement group_id="O4" value="2680" spread="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Total Selumetinib</title>
        <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post dose</time_frame>
        <population>In the moderate group, 2 patients received Selumetinib 25mg and are not included here but are included in the Dose Normalised Cmax outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Mild</title>
            <description>Mild (Child Pugh A) hepatic impaired subjects (all subjects received Selumetinib 50 mg)</description>
          </group>
          <group group_id="O2">
            <title>Moderate</title>
            <description>Moderate (Child Pugh B) hepatic impaired subjects). 6 subjects received Selumetinib 50 mg, 2 received Selumetinib 25mg</description>
          </group>
          <group group_id="O3">
            <title>Severe</title>
            <description>Severe (Child Pugh C) hepatic impaired subjects. All subjects received Selumetinib 20mg.</description>
          </group>
          <group group_id="O4">
            <title>Normal</title>
            <description>Healthy volunteers. All volunteers received Selumetinib 50mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Total Selumetinib</title>
          <population>In the moderate group, 2 patients received Selumetinib 25mg and are not included here but are included in the Dose Normalised Cmax outcome measure</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="741" spread="47"/>
                    <measurement group_id="O2" value="1210" spread="43.2"/>
                    <measurement group_id="O3" value="370" spread="49.8"/>
                    <measurement group_id="O4" value="944" spread="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Normalized AUC, Total Selumetinib</title>
        <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild</title>
            <description>Mild (Child Pugh A) hepatic impaired subjects (all subjects received Selumetinib 50 mg)</description>
          </group>
          <group group_id="O2">
            <title>Moderate</title>
            <description>Moderate (Child Pugh B) hepatic impaired subjects). 6 subjects received Selumetinib 50 mg, 2 received Selumetinib 25mg</description>
          </group>
          <group group_id="O3">
            <title>Severe</title>
            <description>Severe (Child Pugh C) hepatic impaired subjects. All subjects received Selumetinib 20mg.</description>
          </group>
          <group group_id="O4">
            <title>Normal</title>
            <description>Healthy volunteers. All volunteers received Selumetinib 50mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized AUC, Total Selumetinib</title>
          <units>ng*h/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9" spread="39.0"/>
                    <measurement group_id="O2" value="85.1" spread="38.3"/>
                    <measurement group_id="O3" value="84.3" spread="20.1"/>
                    <measurement group_id="O4" value="53.6" spread="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Normalized Cmax, Total Selumetinib</title>
        <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild</title>
            <description>Mild (Child Pugh A) hepatic impaired subjects (all subjects received Selumetinib 50 mg)</description>
          </group>
          <group group_id="O2">
            <title>Moderate</title>
            <description>Moderate (Child Pugh B) hepatic impaired subjects). 6 subjects received Selumetinib 50 mg, 2 received Selumetinib 25mg</description>
          </group>
          <group group_id="O3">
            <title>Severe</title>
            <description>Severe (Child Pugh C) hepatic impaired subjects. All subjects received Selumetinib 20mg.</description>
          </group>
          <group group_id="O4">
            <title>Normal</title>
            <description>Healthy volunteers. All volunteers received Selumetinib 50mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized Cmax, Total Selumetinib</title>
          <units>ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="47.0"/>
                    <measurement group_id="O2" value="23.6" spread="37.4"/>
                    <measurement group_id="O3" value="18.5" spread="49.9"/>
                    <measurement group_id="O4" value="18.9" spread="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Normalized AUC, Unbound Selumetinib</title>
        <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild</title>
            <description>Mild (Child Pugh A) hepatic impaired subjects (all subjects received Selumetinib 50 mg)</description>
          </group>
          <group group_id="O2">
            <title>Moderate</title>
            <description>Moderate (Child Pugh B) hepatic impaired subjects). 6 subjects received Selumetinib 50 mg, 2 received Selumetinib 25mg</description>
          </group>
          <group group_id="O3">
            <title>Severe</title>
            <description>Severe (Child Pugh C) hepatic impaired subjects. All subjects received Selumetinib 20mg.</description>
          </group>
          <group group_id="O4">
            <title>Normal</title>
            <description>Healthy volunteers. All volunteers received Selumetinib 50mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized AUC, Unbound Selumetinib</title>
          <units>ng*h/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.127" spread="41.4"/>
                    <measurement group_id="O2" value="0.259" spread="53.0"/>
                    <measurement group_id="O3" value="0.583" spread="44.9"/>
                    <measurement group_id="O4" value="0.184" spread="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Normalized Cmax, Unbound Selumetinib</title>
        <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild</title>
            <description>Mild (Child Pugh A) hepatic impaired subjects (all subjects received Selumetinib 50 mg)</description>
          </group>
          <group group_id="O2">
            <title>Moderate</title>
            <description>Moderate (Child Pugh B) hepatic impaired subjects). 6 subjects received Selumetinib 50 mg, 2 received Selumetinib 25mg</description>
          </group>
          <group group_id="O3">
            <title>Severe</title>
            <description>Severe (Child Pugh C) hepatic impaired subjects. All subjects received Selumetinib 20mg.</description>
          </group>
          <group group_id="O4">
            <title>Normal</title>
            <description>Healthy volunteers. All volunteers received Selumetinib 50mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized Cmax, Unbound Selumetinib</title>
          <units>ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0409" spread="55.4"/>
                    <measurement group_id="O2" value="0.0716" spread="51.0"/>
                    <measurement group_id="O3" value="0.128" spread="73.0"/>
                    <measurement group_id="O4" value="0.0647" spread="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mild</title>
          <description>Mild (Child Pugh A) hepatic impaired subjects (all subjects received Selumetinib 50 mg)</description>
        </group>
        <group group_id="E2">
          <title>Moderate</title>
          <description>Moderate (Child Pugh B) hepatic impaired subjects). 6 subjects received Selumetinib 50 mg, 2 received Selumetinib 25mg</description>
        </group>
        <group group_id="E3">
          <title>Severe</title>
          <description>Severe (Child Pugh C) hepatic impaired subjects. All subjects received Selumetinib 20mg.</description>
        </group>
        <group group_id="E4">
          <title>Normal</title>
          <description>Healthy volunteers. All volunteers received Selumetinib 50mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Head Ache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In the moderate group, 2 patients received Selumetinib 25mg and are not included in sumaries for AUC and Cmax. Dose normalized parameters are more appropriate for comparisons between groups and are included for all subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gabriella Mariani</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+44 7818 523 899</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

